Wealthstreet Investment Advisors LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,250 shares of the medical device company’s stock, valued at approximately $473,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its position in DexCom by 29.2% in the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after purchasing an additional 1,991,094 shares during the period. Brown Advisory Inc. lifted its position in DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after purchasing an additional 1,515,134 shares during the period. JPMorgan Chase & Co. lifted its position in DexCom by 143.8% in the third quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after purchasing an additional 7,738,678 shares during the period. State Street Corp lifted its position in DexCom by 2.5% in the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares during the period. Finally, AXA lifted its position in DexCom by 10.5% in the third quarter. AXA now owns 1,318,931 shares of the medical device company’s stock worth $64,529,000 after purchasing an additional 124,920 shares during the period.
Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $55.74 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a one year low of $42.62 and a one year high of $86.32.
A number of equities research analysts have weighed in on DXCM shares. Zacks Investment Research downgraded DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. TheStreet cut DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. Northland Securities reaffirmed a “hold” rating and issued a $50.00 price target on shares of DexCom in a report on Thursday, November 2nd. Barclays dropped their price target on DexCom from $60.00 to $57.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Finally, Morgan Stanley dropped their price target on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. DexCom presently has an average rating of “Hold” and an average price target of $67.44.
TRADEMARK VIOLATION NOTICE: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/15/wealthstreet-investment-advisors-llc-invests-473000-in-dexcom-inc-dxcm-stock.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.